Gotham Asset Management, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.

Quarter-by-quarter ownership
Gotham Asset Management, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,608,449
+24.0%
42,106
+17.1%
0.03%
+17.9%
Q2 2023$1,296,825
-22.6%
35,953
-18.0%
0.03%
-31.7%
Q1 2023$1,675,433
+7.3%
43,871
+59.8%
0.04%
-6.8%
Q4 2022$1,561,734
+33.5%
27,447
-7.2%
0.04%
+25.7%
Q3 2022$1,170,000
-12.8%
29,590
-3.0%
0.04%
-18.6%
Q2 2022$1,342,000
-13.5%
30,495
-21.6%
0.04%
-10.4%
Q1 2022$1,551,000
-14.5%
38,902
-13.8%
0.05%
-18.6%
Q4 2021$1,815,000
+90.5%
45,133
+92.6%
0.06%
+51.3%
Q3 2021$953,000
-38.9%
23,435
-31.8%
0.04%
-40.9%
Q2 2021$1,561,000
-19.2%
34,378
-25.8%
0.07%
-23.3%
Q1 2021$1,931,000
+112.9%
46,324
+118.1%
0.09%
+186.7%
Q4 2020$907,000
+65.2%
21,239
+1.7%
0.03%
+66.7%
Q3 2020$549,000
-2.0%
20,890
+0.0%
0.02%
+5.9%
Q2 2020$560,000
+75.5%
20,882
+17.8%
0.02%
+88.9%
Q1 2020$319,000
+54.1%
17,729
+33.0%
0.01%
+125.0%
Q3 2019$207,000
-7.2%
13,334
+2.8%
0.00%0.0%
Q2 2019$223,000
-78.7%
12,970
-79.1%
0.00%
-73.3%
Q2 2018$1,049,000
-53.8%
62,201
-46.4%
0.02%
-53.1%
Q1 2018$2,271,000
+667.2%
115,942
+237.9%
0.03%
+700.0%
Q2 2016$296,000
-23.9%
34,313
+18.5%
0.00%0.0%
Q3 2015$389,000
-53.1%
28,955
-21.1%
0.00%
-42.9%
Q2 2015$829,00036,7010.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Third Security, LLC 19,305,403$233,209,00010.86%
BB BIOTECH AG 7,379,832$89,148,0003.13%
SENZAR ASSET MANAGEMENT, LLC 550,544$6,650,572,0001.72%
SNYDER CAPITAL MANAGEMENT L P 2,232,114$26,964,0001.69%
Sterling Global Strategies LLC 22,000$266,0000.98%
IRIDIAN ASSET MANAGEMENT LLC/CT 9,290,024$112,223,0000.98%
MSD Partners, L.P. 965,000$11,657,0000.94%
DOHENY ASSET MANAGEMENT /CA 130,950$1,582,0000.81%
Taylor Wealth Management Partners 128,110$1,548,0000.69%
Bellevue Group AG 318,000$3,841,0000.69%
View complete list of HALOZYME THERAPEUTICS INC shareholders